Expression of Latent Matrix Metalloproteinase 9 (MMP-9) Predicts Survival in Advanced Ovarian Cancer
- 1 August 2001
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 82 (2) , 291-298
- https://doi.org/10.1006/gyno.2001.6243
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Matrix Metalloproteinases: Biologic Activity and Clinical ImplicationsJournal of Clinical Oncology, 2000
- Matrix MetalloproteinasesJournal of Biological Chemistry, 1999
- Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIcBritish Journal of Cancer, 1999
- Matrix metalloproteinase degradation of extracellular matrix: biological consequencesCurrent Opinion in Cell Biology, 1998
- Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancerBritish Journal of Cancer, 1998
- Prognostic Relevance of MMP-2 (72-kD Collagenase IV) in Gastric CancerOncology, 1998
- General mechanisms of metastasisCancer, 1997
- Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells.Proceedings of the National Academy of Sciences, 1994
- Secretion of extracellular matrix‐degrading proteinases is increased in epithelial ovarian carcinomaInternational Journal of Cancer, 1994
- FACTORS IN THE CAUSATION AND INCIDENCE OF OVARIAN CANCERObstetrical & Gynecological Survey, 1972